Steven J. Adelman

Dr. Steven Adelman is a senior pharmaceutical executive with more than 20 years of experience in Drug Discovery and Therapeutic Intervention in Cardiovascular / Metabolic and Immune Disorders. Currently, he serves as President and CEO of VascularStrategies, a company focused on the assessment and development of therapeutic agents utilizing novel and atypical approaches to Cardiovascular, Inflammatory, and Metabolic Diseases. Dr. Adelman has practiced his expertise as Senior Director Discovery Research at Wyeth Pharmaceuticals where he played a major leadership role in bringing more than 10 pharmacologic agents from discovery research into clinical trials, including breakthrough programs in vascular biology and its relationship to atherosclerosis. Dr. Adelman was also a key initiator and driver of the first Drug-Eluting Stent, the Cypher-stent, a product that has changed the paradigm for the practice of Interventional Cardiology. In addition, Dr. Adelman has authored numerous articles in peer-reviewed journals and presented extensively at numerous scientific symposiums. He is a recognized inventor, with more than 12 patents issued both in the U.S. and internationally. Dr. Adelman is also an elected fellow of the American Heart Association and serves as member and Chair on the review committees of several diabetes and cardiovascular societies.